| SATURDAY, AUGUST 30, 2003 |
| 14:00 - 15:00 |
A PRACTICAL APPROACH TO SUBCUTANEOUS APOMORPHINE
THERAPY IN LATE-STAGE PARKINSON'S DISEASE
Symposium sponsored by Britannia Pharmaceuticals |
| SUNDAY, AUGUST 31, 2003 |
| 13:30 - 15:00 |
OPTIMIZING LEVODOPA THERAPY: THE ROLE OF COMT
INHIBITION
Symposium sponsored by Novartis Pharma AG and
Orion Corporation Orion Pharma |
| |
NEW OPTIONS IN THE MANAGEMENT OF ALZHEIMER'S
DISEASE
Symposium sponsored by Lundbeck |
| 17:30 - 19:00 |
MODERN STROKE MANAGEMENT. FROM ACUTE TREATMENT
TO THE PRoFESS TRIAL
Symposium sponsored by Boehringer-Ingelheim |
| |
WOMEN IN MIND: WOMEN'S ISSUES IN EPILEPSY AND
MIGRAINE
Symposium sponsored by GSK |
| |
MOVEMENT DISORDERS
Symposium sponsored by Amersham |
| MONDAY, SEPTEMBER 1, 2003 |
| 13:30 - 15:00 |
A VOYAGE OF PROGRESS: EXPLORING ADVANCES IN NEUROPATHIC
PAIN
Symposium sponsored by Pfizer Inc. |
| |
TRIED AND TRUSTED: THE USE OF AEDS FROM CONCEPTION
THROUGH CHILDHOOD
Symposium sponsored by Novartis Pharma AG |
| |
RESTLESS LEGS SYNDROME -RLS
Symposium sponsored by Glaxo SmithKline |
| 17:30 - 19:00 |
RATIONAL APPROACH TOWARD IMPROVING THE DIAGNOSIS
AND MANAGEMENT OF MIGRAINE: A SPECTRUM OF EVIDENCE
Symposium sponsored by Pfizer Inc. |
| |
CLINICAL RATIONALE AND EVIDENCE FOR THE USE OF
DOPAMINE AGONISTS IN EARLY PARKINSON'S DISEASE
Symposium sponsored by Boehringer-Ingelheim and Pharmacia |
| |
|
| TUESDAY, SEPTEMBER 2, 2003 |
| 13:30 - 15:00 |
PHASE III TRIALS RESULTS WITH RASAGILINE AS MONOTHERAPY
AND ADJUNCT THERAPY
Symposium sponsored by Lundbeck and Teva Pharmaceuticals |
 |
MAXIMIZING THERAPEUTIC BENEFITS IN DEMENTIA
Symposium sponsored by Pfizer Inc. |
